about
Levetiracetam therapy in patients with brain tumour and epilepsy.Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerHome care for brain tumor patients.The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma.Chemotherapy in neoplastic meningitis.Temozolomide as salvage treatment in primary brain lymphomas.Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases.Brain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.Paraneoplastic Morvan's syndrome following surgical treatment of recurrent thymoma: A case report.Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry studySupportive care in neurooncology.Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.Weight of epilepsy in brain tumor patients.European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma.Cognitive rehabilitation for early post-surgery inpatients affected by primary brain tumor: a randomized, controlled trial.Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).Rehabilitation pathways in adult brain tumor patients in the first 12 months of disease. A retrospective analysis of services utilization in 719 patients.Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.End-of-life care in patients with primary malignant brain tumors: early is better.Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy.Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial.Neuroprotective strategies in the prevention of chemotherapy-induced neuropathies.Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability.Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.Tapentadol in neuropathic pain cancer patients: a prospective open label study.Headache as a presenting symptom of glioma: A cross-sectional study.Palliative and Supportive Care of Patients with Intracranial Glioma.Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients.Outcome and tolerability of topiramate in brain tumor associated epilepsy.Epilepsy in the end-of-life phase in patients with high-grade gliomas.Factors affecting ¹⁸F FDOPA standardized uptake value in patients with primary brain tumors after treatment.Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
P50
Q30483088-34CF6239-8CA9-47E5-829D-40927770A014Q30818191-7F5A3169-CB61-435D-81CB-040329A6E33BQ33625227-2988E8AE-C24F-4674-A61B-4D33226D3980Q34552757-5C27AA7B-23BC-4B61-9EDD-F71C92E1257BQ35206222-5E8373EB-15A2-4348-ADEF-C90024197BCFQ35992345-60B201D1-C4C5-4EA6-939D-B3EE8A709F2AQ36584003-7C1D25E0-0D49-4FE8-A955-DD45A881937AQ36610071-6A4E2F04-C6CA-482F-9685-042E32E2BB94Q37141394-D5B84915-6BEC-4E51-B07C-A010CDAC3919Q37212272-9A74271E-C062-4ACF-A70C-EC4A43D1AABEQ37287991-9C770095-E6EA-42D9-974F-FF1B3623821DQ37747899-366DB3F9-B67B-49E6-A05C-471D3B9775E1Q37779705-E39B6290-78A9-4A67-85BA-7BFE92F0227AQ38092731-78D1E0A7-DC2F-495D-A65B-4ACBC43240D4Q39199891-6613DADF-EF97-415D-9357-BD813818D97DQ39359091-65DEE4BD-790A-4054-99E5-4A5B416956F8Q39418339-65C9EE55-40E6-4E10-99B6-044429BE24ACQ39419874-B9476868-8C48-435F-8A60-AB60ADE9E2F5Q39596664-2C0A8BD9-0988-48CA-A384-0FC924FA869EQ39887655-2980F835-45F6-4FF2-B948-7909D458A025Q41282384-75639110-3099-44C3-9C30-870F77D56F5BQ42681369-4C9C3B2B-0C0C-4EF1-9563-DD74206CF6FDQ43132427-46067AD0-94CD-44C6-BC3A-106DACFD0BC4Q43145540-0F1CCD82-AF48-4B50-B4C0-03DADFBCDE73Q43257040-A4130324-D437-495B-BBA9-F25D66D4395AQ43828519-EA231091-724A-4B2B-9882-200A07C514E2Q44304213-ABC22B6A-6047-4D7C-B47B-A4DD3C28DEDFQ44333806-585B8211-E2E8-4004-BAA9-86CF9E2996D9Q44976158-AFE6FB62-0B34-402C-A0B0-F6EA188955A9Q44977464-F621AF99-FBBE-4D0F-9E7B-E2D61FF4E526Q46414107-9300EEAD-4F86-4E6D-9BF7-6CB12D56FB97Q46911563-77D03FC9-A02B-4C49-871C-F88E828F8905Q47324314-6B5A5E27-CEF5-4B44-B171-393E17A4CAB0Q47375471-5A85B76D-487F-4623-98DB-70B82074E59DQ47824092-68F41F36-60EC-4979-9EB9-F5D8B7D5868EQ48058581-49D4B61C-3F26-432D-964A-6533FEFCD684Q48123337-4C338B38-B859-4382-BD25-CDF2E9A7F284Q48327187-426C36A7-71DA-4B22-BC8D-9710F71B9871Q48358663-80546F31-69F9-4A5C-98E3-F43A7CA941E0Q48440167-BE91194A-459C-4FA2-9CE9-3A976B623F95
P50
description
researcher
@en
wetenschapper
@nl
name
A Pace
@en
A Pace
@nl
type
label
A Pace
@en
A Pace
@nl
prefLabel
A Pace
@en
A Pace
@nl
P106
P31
P496
0000-0002-9407-6916